Phase 1 Study of Oral Decitabine and Tetrahydrouridine (THU) in Patients With High Risk Sickle Cell Disease
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Decitabine (Primary) ; Tetrahydrouridine (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; First in man
- 23 Jan 2018 Planned End Date changed from 1 Dec 2016 to 1 Jun 2018.
- 23 Jan 2018 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2018.
- 01 Sep 2017 Results assessing safety of oral THU-decitabine in patient with sickle cell disease (SCD), were published in the PLOS Medicine.